Patrick Grierson
Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patrick Grierson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07126158 · Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaWashington University School of Medicine · recruiting · Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer · principal investigator
- Ph2NCT07101666 · Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric CancerWashington University School of Medicine · not yet recruiting · Gastric Cancer · principal investigator
- Ph1/Ph2NCT06904378 · ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal AdenocarcinomaWashington University School of Medicine · recruiting · Metastatic Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph1NCT05685602 · CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerNational Cancer Institute (NCI) · suspended · Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- Ph1NCT05187182 · CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerWashington University School of Medicine · recruiting · Gastric Cancer, Esophageal Cancer, Stomach Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting Tumor Intrinsic and Extrinsic Survival Signaling to Overcome Resistance to Radiation Therapy in Pancreatic Cancer.R01CA303033 · NCI · WASHINGTON UNIVERSITY · fiscal years 2026 · $603,499 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDACP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI WILLIAM G HAWKINS · fiscal years 2023 to 2026Named on NCT06904378
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT05685602
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.Oncologist · 202334 citationsRCR 2.5
- Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.Invest New Drugs · 202125 citationsRCR 1.5
- Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.Clin Cancer Res · 202521 citationsRCR 4.2